Century Therapeutics/$IPSC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Ticker
$IPSC
Sector
Primary listing
Employees
78
Headquarters
Website
IPSC Metrics
BasicAdvanced
$372M
-
-$0.11
1.72
-
Price and volume
Market cap
$372M
Beta
1.72
52-week high
$3.04
52-week low
$0.34
Average daily volume
1.4M
Financial strength
Current ratio
5.971
Quick ratio
5.823
Long term debt to equity
25.319
Total debt to equity
27.41
Profitability
EBITDA (TTM)
-1.939
Gross margin (TTM)
12.36%
Net profit margin (TTM)
-8.78%
Operating margin (TTM)
-13.78%
Effective tax rate (TTM)
0.70%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
-3.26%
Return on equity (TTM)
-5.98%
Valuation
Price to revenue (TTM)
1.641
Price to book
1.14
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-1.711
Free cash flow yield (TTM)
-58.45%
Free cash flow per share (TTM)
-1.21
Growth
Revenue change (TTM)
1,556.76%
Earnings per share change (TTM)
-93.12%
3-year revenue growth (CAGR)
175.88%
3-year earnings per share growth (CAGR)
-63.45%
What the Analysts think about IPSC
Analyst ratings (Buy, Hold, Sell) for Century Therapeutics stock.
IPSC Financial Performance
Revenues and expenses
IPSC Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Century Therapeutics stock?
Century Therapeutics (IPSC) has a market cap of $372M as of March 26, 2026.
What is the P/E ratio for Century Therapeutics stock?
The price to earnings (P/E) ratio for Century Therapeutics (IPSC) stock is 0 as of March 26, 2026.
Does Century Therapeutics stock pay dividends?
No, Century Therapeutics (IPSC) stock does not pay dividends to its shareholders as of March 26, 2026.
When is the next Century Therapeutics dividend payment date?
Century Therapeutics (IPSC) stock does not pay dividends to its shareholders.
What is the beta indicator for Century Therapeutics?
Century Therapeutics (IPSC) has a beta rating of 1.72. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.